*Submit your email address to receive conference udpates
BioTrinity 2008 Technology Showcase
The Technology Showcase will be held over both days of the conference, April 15-16, 2008. Delegates may also be interested in the preclinical and clinical stage drug development, diagnostics and medical technology companies presenting in the Company Showcase
Universities, start-up or young spin-out companies and other parties interested in presenting should contact OBN at the earliest opportunity to request a 15 minute presentation slot.
Programme (up to 6 further slots may be allocated):
| Technology Showcase incorporating the Isis Showcase | |
| Tuesday 15th April 2008 - Day One Tech Showcase | |
|
13.00 a2sp Ltd - Suzanne Dilly - Chief Operating Officer Spin out (Therapeutics): Magic Tag Immobilisation Technology for chemical genomics approaches to therapeutic switching a2sp Limited applies its proprietary Magic Tag® discovery technology to exploit the potential of Drug Reprofiling as a source of low-risk, clinic-ready therapeutics. Magic Tag® enables the rapid, cost-effective identification of novel drug-protein interactions allowing the screening of the landscape of existing drugs to identify potential new therapeutic indications. | |
|
13.15 Momentum Bioscience - Bill Mullen, CEO Start up (Diagnostics): Consolidating infectious disease diagnostics The $8bn infectious disease diagnostics market uses several technology platforms to provide a complete testing menu. For example, a lab may test for MRSA using culture, C. difficile toxin using immunoassay and viral respiratory infections using PCR. Momentum Bioscience’s Pan-IDD technology allows all these tests to run on a single instrument already available in the hospital laboratory. First products are a best-in-class, <4hr MRSA culture test and a test for C. difficile. The Company is raising £200k from founders and grants to develop prototypes. In H1 2009 it will seek £4m funding round with first product launch in late 2010. | |
|
13.30 Organox (spin-out candidate) - Isis Innovation, University of Oxford
The OrganOx device has the potential to improve the quality and double the annual number of liver transplants. To date, it has been used in over 300 pre-clinical procedures and 50 transplants. Applying this platform technology to preservation of other organs, to organ preconditioning and targeted cancer therapy, would address a $2bn+ market. Funding is sought to complete preclinical trials and build clinical grade prototypes. | |
|
13.45 Oxford Neotest (spin-out candidate) - Isis Innovation, University of Oxford
Oxford Neotest supplies simple, robust bioreactor technology for cell culture and 3-D tissue growth, targeting firstly the research consumables market and also the need for better pre-clinical toxicology and efficacy screening amongst pharma and fine chemicals companies. A development contract with big pharma has been secured. Oxford Neotest is seeking to fund an initial 2 years of operations before the business becomes sustainable. | |
|
14.00 Oxford Medistress - Spin-out - Isis Innovation, University of Oxford
Oxford Medistress, a spin-out company from the University of Oxford, is commercialising a novel in vitro blood test device which aims to provide the first objective, quantitative measurement of stress. The rapid test, which works from a single drop of blood, is already being used to monitor recovery in footballers from English Premiership football clubs. | |
|
14.15 Imaging agents for the central nervous system (Licensing Opportunity 2468) - Isis Innovation, University of Oxford
Oxford researchers have developed the first of a class of novel sugar-targeted imaging contrast agents for use with MRI brain scanning. The invention has the scope to improve the diagnosis and monitoring of multiple sclerosis and other inflammatory diseases of the central nervous system, by providing a more advanced method of detecting damage to the blood brain barrier. | |
|
15:00 Meningitis B vaccine (Licensing Opportunity 1538) - Isis Innovation, University of Oxford
A new approach to designing meningitis vaccines broadly protective against many bacterial strains (including the B serogroup), has been developed by researchers from the Peter Medawar Building for Pathogen Research and the Department of Paediatrics, in collaboration with scientists from the National Institute for Biological Standards and Controls. Funding has been secured from the Wellcome Trust to take a lead candidate into Phase I trials in 2010. | |
|
15.15 Prognostic test for breast cancer (Licensing Opportunity 3203) - Isis Innovation, University of Oxford
Oxford researchers have identified an easily-detectable marker (a microRNA) which is closely correlated with breast cancer survival. This test provides the scope to ensure that patients receive the most effective and appropriate treatment. | |
|
15.30 Novel broad-spectrum antiviral against envelope viruses Peter Crocker, Manager, AST Associates | |
| Wednesday 16th April 2008 - Day Two Tech Showcase | |
| 09.55 Welcome - Technology Showcase Day 2 | |
|
10.00 ARID - Automatic retinal image distancing for diabetic retinopathy (Licensing Opportunity 2158) - Isis Innovation, University of Oxford
ARID is a computer system that highlights change between retinal images over time and offers a new method for the assessment of diabetic retinopathy. ARID can be used as a care based system where clinicians will be able to detect change in the retina instantly as soon as a new image is taken. | |
|
10.15 Molecular shape recognition software (Licensing Opportunity 2932) - Isis Innovation, University of Oxford
Oxford researchers have identified a new method for searching a molecular database for compounds that most closely resemble the shape of a molecule of known activity. This addresses one of the big problems in pharmaceutical R&D: screening out the potential drug candidates from a huge library of molecules. | |
| 10.30-11.00 Refreshments, Networking and Exhibition | |
|
11.00 FMRIB software library (Licensing Opportunity 3497) - Isis Innovation, University of Oxford
Scientists at Oxford University have now released the latest version (4.0) of their FSL software, which allows clinicians and researchers to analyse images of the brain, providing insights and improved treatment of conditions including schizophrenia, Alzheimer’s disease, multiple sclerosis, epilepsy, and Parkinson’s. The software is available for commercial license. | |
|
11.15 Swarm intelligence software (Licensing Opportunity 2536) - Isis Innovation, University of Oxford
Research at the University of Oxford has enabled the use of an artificial intelligence technique based on the concept of swarm intelligence to derive from NMR data the 3D structure of proteins unsuitable for analysis by the traditional method of x-ray crystallography. | |
|
11.30 OPRA Software – Optimising Resource Allocation in Pharmaceutical Research (Licensing Opportunity 3284) - Isis Innovation, University of Oxford
A new software package incorporates sophisticated economic modelling to determine optimal resource allocation during preclinical pharmaceutical research. The software is the culmination of over thirty years of research and development at Oxford. | |
|
11.45 Domainex- two steps forward Dr Eddy Littler, CEO, Domainex | |
Speaker qualification if you are thinking about participating as a speaker?
Young start-ups, spin outs and licensing opportunities from Universities, Institutes and other organisations such as NHS Innovations, MRC Technology, Cancer Research Techology, Isis Innovation as well as licensing opportunities from SMEs. Please note that there is no geographic limitation on applicants. Up to 16 opportunities from Isis Innovation and Warwick Ventures will be presented. Business Development Managers for Tech Transfer arms of Universities which wish to present specific opportunities should contact OBN to request a speaking slot which will be judged on merit.
About the Selection Process
An informed decision will be made based upon information supplied by companies, as well as business intelligence which OBN has gathered through research. Companies who are not selected to present are encouraged to participate in the one-to-one partnering elements of the meeting for the purposes of business development. All Technology Showcase speakers must hold a full and valid registration for the day they are speaking.
Criteria for Selection
- Consideration will be given to company's USP, or the USP of their leading product, the route-to-market, exit route and milestones.
- Consideration is given to revenue streams, demonstrated fund-raising ability, and proximity to market
- Funding, grants and awards
- Recent deal-making success
- Innovation in product or business strategy
- Preference is given to recent spin out and licensing opporunities
- Control the IP needed to meet business strategy
PROJECT PARTNERS
